olx10010
Nucleic acidexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started May 21, 2018 (NCT03569267)
Timeline
Indications
Studied for
Mechanism of action
- Connective tissue growth factorINHIBITOR
CCN2 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04877756 | Phase 2 | Aug 31, 2021 | Alira Health, OliX Pharmaceuticals |
| NCT03569267 | Phase 1 | May 21, 2018 | Covance, OliX Pharmaceuticals |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| OliX Pharmaceuticals | For profit | 2 | 2 | 2 | 2018 |
| Alira Health | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Covance | For profit | 1 | 0 | 1 | 2018 |
3 organizations
Page 1 / 1